Composition for inhibiting malassezia and preparation method and application thereof

Abstract

The invention belongs to the field of medicines and cosmetics, and particularly relates to a composition for inhibiting malassezia as well as a preparation method and application thereof. The composition is prepared from the following components in parts by mass: 50 to 90 parts of myricetin compounds and 10 to 50 parts of quercetin compounds. The drug combination effect of the myricetin compound and the quercetin compound is researched for the first time, it is found that the myricetin compound and the quercetin compound have the synergistic interaction effect and the monomer stability improving effect, and it is further obtained that the dihydromyricetin and the troxerutin have the good synergistic effect when the mass ratio of the dihydromyricetin to the troxerutin ranges from 0.6: 0.4 to 0.9: 0.1. Bacteriostatic experiment results show that the myricetin and quercetin composition has an effect of inhibiting the growth of malassezia instead of directly killing the malassezia, and has a stronger bactericidal effect when being matched with gallic acid components for use. The composition disclosed by the invention can be prepared into medicines, daily chemical products and the like, is used for treating skin diseases caused by malassezia, provides an important basis for clinical application research, and has a wide application prospect.

Description

Technical Field

[0001] The invention belongs to the field of medicine and cosmetics, and particularly relates to a composition for inhibiting Malassezia, a preparation method and application thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Malassezia is a common fungus on human skin, especially in oily skin or areas with high sebaceous gland density, where the proportion of Malassezia in the total number of fungi can be close to 100%. Common species of Malassezia on human skin include Malassezia restricta, Malassezia globosa, Malassezia sympodiala, Malassezia furfur, etc. Malassezia plays a dual role on the skin. The beneficial side includes participating in the formation of skin immune homeostasis and flora homeostasis, and does not cause disease on normal skin; however, in some cases, such as vigorous sebaceous gland secretion, hyperhidrosis, immune dysfunction, long-term use of certain drugs (such as glucocorticoids), improper diet, or living in a hot and humid environment, Malassezia may over-proliferate and cause skin diseases such as tinea versicolor, Malassezia folliculitis, and seborrheic dermatitis. The metabolites of Malassezia can trigger inflammatory reactions and damage the scalp environment, leading to problems such as dandruff, itchy scalp, and hair loss. Existing studies have shown that controlling Malassezia is beneficial to reducing scalp problems such as dandruff, scalp inflammation, and seborrheic dermatitis.

[0004] At present, ketoconazole, piroctone olamine, pyrithione zinc, climbazole, etc. are mainly used to control Malassezia in topical medicines and personal care products. They are all fungicides, but studies have found that Malassezia has developed resistance to antifungal agents such as ketoconazole. Natural plant extracts have safe and good antibacterial activity. Therefore, screening plant extracts with antibacterial activity against Malassezia and applying them in actual treatment has great scientific significance and practical value. Summary of the invention

[0005] In order to overcome the deficiencies of the prior art, the present invention provides a composition for inhibiting Malassezia, and a preparation method and application thereof. The present invention uses myricetin components in combination with quercetin components, which can synergistically inhibit the effect of Malassezia, and improve the stability of the monomer components. In the in vitro antibacterial test of Malassezia, when used alone within a specific concentration range, myricetin components have antibacterial properties, while quercetin components have no antibacterial properties, but the combination of the two shows a synergistic effect, and the antibacterial effect is enhanced at the same concentration, indicating that the two have synergy. In the test, it was found that myricetin components are prone to oxidation, changing from colorless to red on the plate, and quercetin components can reduce the discoloration of myricetin components and play a protective role.

[0006] In order to achieve the above object, the present invention is implemented by the following technical solutions:

[0007] In a first aspect, the present invention provides a composition for inhibiting Malassezia, comprising the following components, measured by mass: 10 to 90 parts of myricetin compounds and 10 to 90 parts of quercetin compounds; the myricetin compounds are selected from at least one of myricetin, dihydromyricetin and Agave sphenanthera extract; the quercetin compounds are selected from at least one of quercetin, rutin, troxerutin, glucosylrutin, dihydroquercetin and Sophora japonica bud extract.

[0008] Furthermore, the composition comprises the following components in parts by mass: 50 to 90 parts of myricetin compounds and 10 to 50 parts of quercetin compounds.

[0009] Furthermore, the composition comprises the following components by mass: 66-70 parts of myricetin and 30-40 parts of Sophora japonica bud extract; or, 70-90 parts of dihydromyricetin and 10-30 parts of glucosylrutin; or, 85-95 parts of myricetin and 5-15 parts of dihydroquercetin; or, 80-90 parts of Agave sphenanthera extract and 10-20 parts of troxerutin; or, 40-60 parts of dihydromyricetin and 10-90 parts of troxerutin.

[0010] Furthermore, the composition also includes a compound or extract containing a gallic acid group, the mass fraction of which is 10 to 50 parts.

[0011] In a second aspect, the present invention provides a method for preparing the composition of the first aspect, specifically comprising: dissolving the composition in polyols to prepare a solution;

[0012] The polyol is 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, 1,2-pentanediol or 1,2-hexanediol. Preferably, the polyol is 1,3-butylene glycol.

[0013] Alternatively, the polyol is mixed with water to form a solution, and the mass percentage of the polyol in the solution is 10 to 99%. Preferably, the mass percentage of the polyol in the solution is 50 to 80%.

[0014] Furthermore, in the polyol aqueous solution, the mass percentage of the composition is 1 to 40%, preferably 2 to 10%.

[0015] In a third aspect, the present invention provides the use of the composition described in the first aspect or the composition obtained by the preparation method described in the second aspect in the preparation of a product for preventing or treating skin diseases caused by Malassezia, wherein the skin diseases include tinea versicolor and Malassezia folliculitis.

[0016] Furthermore, the product is a medicine or a daily chemical product.

[0017] Furthermore, the medicine or daily chemical product is made of the composition and auxiliary materials allowed by the medicine or daily chemical product, and the mass percentage of the composition in the medicine or daily chemical product is 0.00001% to 99%.

[0018] Furthermore, the medicine or daily chemical product is an external-use product, the external-use product of the medicine is a lotion, ointment, emulsion or spray; the external-use product of the daily chemical product is a shampoo, conditioner, cream, hand soap, shower gel, essence or lotion, soap.

[0019] One or more technical solutions of the present invention described above achieve the following beneficial effects:

[0020] 1. The present invention systematically studies the antibacterial activity of myricetin compounds against Malassezia, and for the first time studies the combined use of myricetin compounds and quercetin compounds, and finds that the two have a synergistic effect and improve the stability of the monomers, and obtains a composition for inhibiting Malassezia, and the mass ratio of dihydromyricetin and troxerutin has a good synergistic effect in the range of 0.6:0.4 to 0.9:0.1. The results of the antibacterial experiment show that the myricetin + quercetin composition has an inhibitory effect on the growth of Malassezia rather than a direct killing effect, and the composition has a stronger bactericidal effect when used in combination with gallic acid components.

[0021] 2. The natural product of the composition of the present invention has the characteristics of stable properties, small toxic and side effects, and remarkable effects. It is found through in vitro drug sensitivity experiments that myricetin compounds have a significant inhibitory effect on Malassezia, and it is further found that myricetin compounds and quercetin compounds have a synergistic effect. The composition of the present invention can be prepared as medicines, daily chemical products, etc., for the treatment of skin diseases caused by Malassezia, such as seborrheic dermatitis, dandruff, etc. Compared with synthetic drugs, the composition of the present invention has the advantages of natural non-toxicity, little damage to the environment, and low stimulation, which provides an important basis for clinical application research and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0023] Figure 1 This is an antibacterial zone test on an in vitro antibacterial plate, wherein, Figure a: the upper left is a positive control, piroctone olamine salt 0.05%, the upper right is dihydromyricetin 0.5%, and the middle and lower are myricetin 0.5%; Figure b: the upper left is dihydromyricetin 0.15% + troxerutin 0.05%, the lower left is dihydromyricetin 0.5%, the upper right is troxerutin 0.5%, and the lower right is dihydromyricetin 0.2%; % represents drug concentration (%, w / w), the same below;

[0024] Figure 2 The antibacterial zone test of different ratio compositions, wherein A is 0.200% dihydromyricetin, B is 0.190% dihydromyricetin + 0.010% troxerutin, C is 0.180% dihydromyricetin + 0.020% troxerutin, D is 0.170% dihydromyricetin + 0.030% troxerutin, and E is 0.160% dihydromyricetin + 0.040% troxerutin;

[0025] Figure 3 It is the Log value of the number of viable bacteria in the culture medium at different time periods. DETAILED DESCRIPTION

[0026] A typical embodiment of the present invention is a composition for inhibiting Malassezia, which is composed of myricetin compounds and quercetin compounds.

[0027] For myricetin compounds, natural or synthetic myricetin, myricetin glycosides, dihydromyricetin can be used, and plant extracts with the above ingredients as characteristic or main ingredients can also be used, especially the following plants: ① plants of the genus Ampelopsis, such as extracts of A.grossedentata, A.megalophylla, and A.cantoniensis; ② plants of the genus Myrica, such as extracts of M.cerifera; ③ plants of the genus Vaccinium (Cranberry), such as extracts of Vaccinium myricum (Lavender), such as extracts of Vaccinium truncatum (Lavender ... Vaccinium) plants, such as extracts of V. macrocarpon, V. myrtillus, V. angustifolium, V. vitis-Idaea, V. uliginosum; ④ Rumex plant extracts, such as extracts of R. occidentalis, R. acetosella, R. crispus; or a mixture of the above ingredients.

[0028] For quercetin compounds, naturally extracted or synthetic quercetin, glucosylrutin, troxerutin, dihydroquercetin, rutin, quercetin, hyperoside, etc. can be used, or plant extracts with the above ingredients as characteristic ingredients or main ingredients, such as Sophora japonica flower / fruit / bud extract, buckwheat (Polygonum fagopyrum) extract, larch (Larix spp.) extract; or a mixture of the above ingredients can be used.

[0029] In one or more examples of this embodiment, the composition comprises the following components in parts by mass: 10 to 90 parts of myricetin compounds and 10 to 90 parts of quercetin compounds.

[0030] In one or more examples of this embodiment, the composition comprises the following components in parts by mass: 50 to 90 parts of myricetin compounds and 10 to 50 parts of quercetin compounds.

[0031] In one or more examples of this embodiment, the myricetin compound is selected from at least one of myricetin, dihydromyricetin and Ampelopsis grossedentata extract; the quercetin compound is selected from at least one of quercetin, rutin, troxerutin, glucosylrutin, dihydroquercetin and Sophora japonica bud extract.

[0032] In one or more examples of this embodiment, the composition comprises the following components by weight: 66-70 parts of myricetin and 30-40 parts of Sophora japonica bud extract.

[0033] In one or more examples of this embodiment, the composition comprises the following components by mass: 70 to 90 parts of dihydromyricetin and 10 to 30 parts of glucosylrutin.

[0034] In one or more examples of this embodiment, the composition comprises the following components by weight: 85-95 parts of myricetin and 5-15 parts of dihydroquercetin.

[0035] In one or more examples of this embodiment, the composition comprises the following components by mass: 80-90 parts of Ampelopsis grossedentata extract and 10-20 parts of troxerutin.

[0036] In one or more examples of this embodiment, the composition comprises the following components by weight: 40 to 60 parts of dihydromyricetin and 10 to 90 parts of troxerutin.

[0037] In one or more examples of this embodiment, the composition further comprises a compound or extract containing a gallic acid group, the mass fraction of which is 10 to 50 parts.

[0038] Among them, the compound or extract containing gallic acid groups can use tea polyphenols rich in gallic acid groups, which are extracts of tea (Camellia sinensis). Tea polyphenols (Camellia sinensis polyphenols) are also called tea catechins (Camellia sinensis catechins) or tea leaf extracts (Camellia sinensisleaf extract), which are rich in catechin components such as epicatechin gallate, epigallocatechin gallate (EGCG), and epigallocatechin; or esters formed by gallic acid and alcohols, especially C1-C8 fatty alcohols, such as propyl gallate, octyl gallate, etc.; persimmon (Diospyros kaki) extracts, European chestnut (Castanea sativa) extracts, Japanese chestnut (Castanea crenata) extracts, pomegranate (Punica granatum) extracts, etc. rich in tannins (galloyl glucose) or ellagic acid can also be used; or mixtures of the above ingredients can be used.

[0039] In one or more examples of this embodiment, the composition comprises the following components in parts by mass: 60 to 80 parts of myricetin, 10 to 30 parts of tea polyphenols, and 5 to 15 parts of quercetin.

[0040] A second typical embodiment of the present invention is a method for preparing a composition for inhibiting Malassezia, specifically comprising: dissolving the composition formula in the first embodiment in a polyol to prepare a solution;

[0041] In one or more examples of this embodiment, the polyol is 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, 1,2-pentanediol or 1,2-hexanediol. Preferably, the polyol is 1,3-butylene glycol.

[0042] Alternatively, the polyol is mixed with water to form a solution, and the mass percentage of the polyol in the solution is 10 to 99%. Preferably, the mass percentage of the polyol in the solution is 50 to 80%.

[0043] In one or more examples of this embodiment, in the polyol aqueous solution, the mass percentage of the composition is 1 to 40%, preferably 2 to 10%.

[0044] A third typical embodiment of the present invention provides the use of the composition described in the first embodiment or the composition prepared by the second embodiment in the preparation of a product for preventing or treating skin diseases caused by Malassezia, wherein the skin diseases include but are not limited to tinea versicolor (PV), Malassezia folliculitis (MF), seborrheic dermatitis / dandruff (SD / D), and atopic dermatitis (AD).

[0045] In one or more examples of this embodiment, the product is a medicine or a daily chemical product.

[0046] In one or more examples of this embodiment, the medicine or daily chemical product is made of the composition and an auxiliary material allowed by the medicine or daily chemical product, and the medicine or daily chemical product is an external product, and the external product of the medicine is a lotion, an ointment, an emulsion or a spray; the external product of the daily chemical product is a shampoo, a conditioner, a cream, a hand soap, a shower gel, an essence or an emulsion, and a soap. In the medicine or daily chemical product, the mass percentage of the composition is 0.00001% to 99%, preferably 2 to 10%.

[0047] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0048] The present invention is further described in conjunction with specific examples. The following examples are only for explaining the present invention and are not intended to limit the content thereof. If the specific experimental conditions are not specified in the examples, they are usually carried out according to conventional conditions or the conditions recommended by the reagent company; the reagents and consumables used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0049] Example 1: Effect of combined use of myricetin compounds and quercetin compounds

[0050] Materials and methods

[0051] Myricetin (≥98%, Chengdu Desite), dihydromyricetin (≥98%, Chengdu Desite), rutin (≥98%, Chengdu Desite), quercetin (≥98%, Chengdu Desite), dihydroquercetin (≥98%, Chengdu Desite), Ampelopsis serrulata extract (dihydromyricetin ≥75%, Xi'an Sinot Biotechnology), Sophora japonica bud extract (rutin ≥10%, Xi'an Sinot Biotechnology), troxerutin (≥97%, Baichuan Kangze), glucosylrutin (≥95%, Anyike Biotechnology). The above ingredients are dissolved in 70% butanediol at 3.0% w / w and added to pure water to prepare a specific concentration aqueous solution and used as soon as possible.

[0052] The experimental strain was Malassezia ATCC 44344, purchased from Shanghai ELISA, which had extracellular lipase activity and could form a fat hydrolysis transparent zone around the colonies on the oil plate.

[0053] The components of the culture medium are as follows: based on the weight of added water, 5 parts of yeast extract powder, 2 parts of polyglycerol fatty acid ester, 2 parts of Tween80, 15 parts of vegetable oil, 5 parts of dipotassium hydrogen phosphate trihydrate, 5 parts of disodium hydrogen phosphate dodecahydrate, 1 part of magnesium sulfate heptahydrate, 1000 parts of water, natural pH, and 20 parts of agar are added to prepare a solid culture medium; sterilize at 121°C for 15 minutes and set aside for use in activation culture of strains and antibacterial detection, and aerobic culture at 37°C.

[0054] In vitro antibacterial test was performed by applying 0.1 ml of fresh culture solution of Malassezia on the plate, and then adding 0.1 ml of the test solution to each Oxford cup. After aerobic culture at 37°C for 24 hours, the presence and diameter of the inhibition zone were observed and measured. The results are shown in Table 1. Figure 1 a. The results showed that myricetin components or extracts rich in myricetin components had a significant inhibitory effect on indicator bacteria. There was a discoloration phenomenon during the antibacterial process, which was caused by oxidation due to contact with air. Quercetin components did not show antibacterial effect.

[0055] Table 1. Diameters of inhibition zones of different ingredients or combinations against Malassezia

[0056] Serial number Element Concentration (%, w / w) Diameter of inhibition zone / mm Remark Myricetin 0.10 7.0 Antibacterial area red 0.20 16.0 Antibacterial area red 0.50 23.5 Antibacterial area red Dihydromyricetin 0.10 8.0 Antibacterial area pink 0.20 14.5 Antibacterial area pink 0.50 25.0 Antibacterial area pink Ampelopsis serrulata Extract 0.10 none Antibacterial area brown 0.20 8.5 Antibacterial area brown 0.50 17.0 Antibacterial area brown Quercetin 0.10～0.50 none none Rutin 0.10～0.50 none none Troxerutin 0.10～0.50 none none Glucosylrutin 0.10～0.50 none none Dihydroquercetin 0.10～0.50 none none Sophora japonica bud extract 0.10～0.50 none none

[0057] The combination of myricetin and quercetin was tested with 0.15% dihydromyricetin + 0.05% troxerutin. The diameter of the inhibition zone was ~20 mm, showing an effect exceeding that of 0.2% dihydromyricetin, and there was no oxidative discoloration. Figure 1 b, indicating that the two have a synergistic effect. The tests on the combinations of other myricetin components and quercetin components all showed similar synergistic effects, indicating that the two have a synergistic effect.

[0058] Taking dihydromyricetin and troxerutin as the objects, the ratio of the two was further studied, the method was the same as above, and the results are shown in Table 2. In the combination of dihydromyricetin and troxerutin, the optimal mass ratio of the two is in the range of 0.6:0.4 to 0.9:0.1, which has a good synergistic effect. See the example picture Figure 2 .

[0059] Table 2 Data table of synergistic antibacterial effect of dihydromyricetin and troxerutin

[0060]

[0061] Example 2: Antibacterial experiment of the Malassezia inhibition composition

[0062] Experimental strains: same as in Example 1.

[0063] Two compositions were prepared, based on the mass fraction, composition ① had the following components: 85 parts of Ampelopsis serrulata extract (dihydromyricetin ≥ 75%) and 15 parts of Troxerutin; composition ② had the following components: 70 parts of myricetin, 10 parts of quercetin, and 20 parts of tea polyphenols. The two composition formulas were dissolved in 70% butylene glycol solution at 5% w / w and set aside.

[0064] Liquid culture medium formula: based on the weight of water added, 5 parts of yeast extract powder, 2 parts of polyglycerol fatty acid ester, 2 parts of Tween80, 15 parts of vegetable oil, 5 parts of dipotassium hydrogen phosphate trihydrate, 5 parts of disodium hydrogen phosphate dodecahydrate, 1 part of magnesium sulfate heptahydrate, 1000 parts of water, pH natural; sterilize at 121℃ for 15 minutes before use, used for strain activation culture and antibacterial detection, aerobic culture at 37℃. Plate count medium is composed of: based on the weight of water added, 5 parts of yeast extract powder, 5 parts of peptone, 3 parts of Tween80, 3 parts of polyethylene glycol lipid, 1000 parts of water, pH natural; sterilize at 121℃ for 15 minutes before use, the medium is transparent after solidification and can be used for plate count, aerobic culture at 37℃.

[0065] The Malassezia strain was inoculated from the plate into a liquid culture medium tube and then cultured at 37°C for 48 hours with shaking. After the seed solution was inoculated into the liquid culture medium at 2% v / v, different treatments were added, which were numbered as follows:

[0066] CK: blank control, without adding any antibacterial or bactericidal substances;

[0067] A: Butanediol solution of composition ① was added to the liquid culture medium at 2.0% v / v;

[0068] B: Butanediol solution of composition ②, added to the liquid culture medium at 2.0% v / v;

[0069] C: Positive control, ketoconazole (fungicide) was added to the liquid culture medium at 0.01% w / w.

[0070] The above treatments were cultured in a shaking incubator at 37°C for 72 hours, and samples were taken every 24 hours for detection of the change in viable bacterial count after gradient dilution. The results are shown in Table 3. The Log value of the viable bacterial count is shown in Figure 3 Compared with the initial viable count concentration at 0 hours, the viable count concentration of the blank control group increased by more than 100 times after 24 hours of culture, and entered the decay phase at 48 hours and the viable count began to decrease; the viable count concentration of group A increased by only about 2 times after 24 hours and decreased at a relatively slow rate; both groups B and C showed bactericidal effects, and the viable count decreased rapidly, decreasing by 35 to 84 times after 24 hours, and could not be detected at a specific dilution after 72 hours.

[0071] Table 3 Changes in the number of viable bacteria in the culture medium at different time periods

[0072] CFU / ml 0hour 24hour 48hour 72hour CK 1.85E7 2.86E9 2.00E8 / A 1.85E7 3.42E7 1.1E5 2.90E4 B 1.86E7 5.30E5 573 ＜100 C 1.82E7 2.17E5 50 ＜10

[0073] The above results show that composition ① has an inhibitory effect on the growth of Malassezia rather than a direct killing effect. The number of live bacteria in 24 hours increased but was only about 2 times the initial number of live bacteria. Composition ② has a stronger bactericidal effect than composition ①.

[0074] Example 3: In vitro antibacterial experiment of the Malassezia inhibition composition

[0075] Experimental strains: same as in Example 1.

[0076] Two compositions were prepared, and the compositions and preparation methods were the same as in Example 2.

[0077] The test was conducted according to the "8 microbial in vitro simulation test" method in "T / GDCA 010-2022 Anti-dandruff Product Anti-dandruff Efficacy Test Method". The two prepared combinations of butanediol solutions were dissolved in 3% butanediol aqueous solution at 2% v / v, shaken well, 0.1 ml was applied to pig skin, dried and smeared with Malassezia suspension, cultured for 48 hours and recovered for culture. The specific operation is shown in the above standard document. The results are shown in Tables 4 and 5. The results show that the above composition has a significant effect of inhibiting the growth of Malassezia.

[0078] Table 4 Results of in vitro simulation test of composition ①

[0079]

[0080] Statistical results: T test value 3.97×10 -12 , there is a very significant difference between the two.

[0081] Table 5 Results of in vitro simulation test of composition ②

[0082]

[0083]

[0084] Statistical results: T test value 4.50×10 -13 , there is a very significant difference between the two.

[0085] The results showed that both compositions had a significant effect in inhibiting the growth of Malassezia, and composition ② supplemented with tea polyphenols had a better effect.

[0086] Example 4: Preparation of spray

[0087] Spray A: 20 parts of anhydrous ethanol, 5 parts of glycerin, 1.5 parts of RH-60, 0.17 parts of Ampelopsis grossedentata extract, 0.03 parts of troxerutin, 1 part of vitamin C, 0.1 parts of citric acid, and deionized water to 100 parts, mix well and can.

[0088] Spray B: 20 ​​parts of anhydrous ethanol, 5 parts of glycerin, 1.5 parts of RH-60, 0.14 parts of myricetin, 0.02 parts of quercetin, 0.04 parts of tea polyphenols, 1 part of vitamin C, 0.1 parts of citric acid, and deionized water to 100 parts, mix well and can.

[0089] Example 5: Preparation of Essence

[0090] Essence A: 5 parts of propylene glycol, 1 part of jojoba wax PEG-120 ester, 0.5 parts of panthenol, 0.5 parts of hydroxyethyl cellulose, 0.5 parts of p-hydroxyacetophenone, 0.5 parts of 1,2-hexanediol, 0.3 parts of PEG-40 hydrogenated castor oil, 0.1 parts of butylene glycol, 0.17 parts of Ampelopsis serrulata extract, 0.03 parts of troxerutin, 0.1 parts of disodium EDTA, and deionized water to 100 parts.

[0091] Preparation method:

[0092] (1) Add water, propylene glycol, disodium EDTA and panthenol into an emulsifying pot, heat to 80°C, and stir until dissolved;

[0093] (2) adding jojoba wax PEG-120 ester and p-hydroxyacetophenone, stirring until dissolved, and cooling to 45° C.;

[0094] (3) Add PEG-40 hydrogenated castor oil, 1,2-hexanediol, butylene glycol, Ampelopsis serrulata extract, and troxerutin into an emulsifying pot, stir, and cool to 38° C. to obtain the product.

[0095] Essence B: 5 parts of propylene glycol, 1 part of jojoba wax PEG-120 ester, 0.5 parts of panthenol, 0.5 parts of hydroxyethyl cellulose, 0.5 parts of p-hydroxyacetophenone, 0.5 parts of 1,2-hexanediol, 0.3 parts of PEG-40 hydrogenated castor oil, 0.1 parts of butylene glycol, 0.14 parts of myricetin, 0.02 parts of quercetin, 0.04 parts of tea polyphenols, 0.1 parts of disodium EDTA, and deionized water to 100 parts.

[0096] The preparation steps are as follows:

[0097] (1) Add water, propylene glycol, disodium EDTA and panthenol into an emulsifying pot, heat to 80°C, and stir until dissolved;

[0098] (2) adding jojoba wax PEG-120 ester and p-hydroxyacetophenone, stirring until dissolved, and cooling to 45° C.;

[0099] (3) Add 1,2-hexanediol, butanediol, myricetin, quercetin and tea polyphenols into an emulsifying pot, stir and cool to 38°C to obtain the product.

[0100] Example 6: Preparation of Shampoo

[0101] A shampoo A for resisting Malassezia comprises a component and a component, wherein the component a consists of 40 parts of sodium laureth sulfate, 6 parts of cocamidopropyl betaine, 4 parts of APG, 0.1 parts of EDTA-Na2 and 3 parts of polyquaternium-55; the component b consists of 0.17 parts of ampelopsis serrulata extract, 0.03 parts of troxerutin, an appropriate amount of citric acid, an appropriate amount of ammonium chloride, 0.01 parts of essence and 0.01 parts of preservative, and the amount is supplemented to 100 parts with water.

[0102] The preparation steps are as follows:

[0103] (1) First, add EDTA-Na2 into deionized water and stir until dissolved;

[0104] (2) Heat the system to about 60°C, add the other ingredients of component a in sequence, and stir until dissolved;

[0105] (3) The system is cooled to 40°C, the pH is adjusted to less than 7 with citric acid, and the other ingredients of component B are added and stirred evenly.

[0106] A shampoo B for resisting Malassezia comprises a component and a component b, wherein the component a consists of 40 parts of sodium laureth sulfate, 6 parts of cocamidopropyl betaine, 4 parts of APG, 0.1 parts of EDTA-Na2 and 3 parts of polyquaternium-55; the component b consists of 0.14 parts of myricetin, 0.02 parts of quercetin, 0.04 parts of tea polyphenols, an appropriate amount of citric acid, an appropriate amount of ammonium chloride, 0.01 parts of essence and 0.01 parts of preservatives, and the amount of water is supplemented to 100 parts.

[0107] The preparation steps are the same as above.

[0108] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A composition for inhibiting Malassezia, characterized in that: The invention comprises the following components by weight: 10 to 90 parts of myricetin compounds and 10 to 90 parts of quercetin compounds; the myricetin compounds are selected from at least one of myricetin, dihydromyricetin and Agave sphenanthera extract; the quercetin compounds are selected from at least one of quercetin, rutin, troxerutin, glucosylrutin, dihydroquercetin and Sophora japonica bud extract.

2. The composition according to claim 1, characterized in that The composition comprises the following components by weight: 50 to 90 parts of myricetin compounds and 10 to 50 parts of quercetin compounds.

3. The composition according to claim 1, characterized in that The composition comprises the following components by weight: 66-70 parts of myricetin and 30-40 parts of Sophora japonica bud extract; or 70-90 parts of dihydromyricetin and 10-30 parts of glucosylrutin; or 85-95 parts of myricetin and 5-15 parts of dihydroquercetin; or 80-90 parts of Agave sphenanthera extract and 10-20 parts of troxerutin; or 40-60 parts of dihydromyricetin and 10-90 parts of troxerutin.

4. The composition according to claims 1-3, characterized in that It also includes compounds or extracts containing gallic acid groups, with a mass fraction of 10 to 50 parts.

5. The method for preparing the composition according to claims 1-4, characterized in that: The composition is dissolved in a polyol to prepare a solution; the polyol is 1,2-propylene glycol, 1,3-propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, 1,2-pentanediol or 1,2-hexanediol, preferably, the polyol is 1,3-butylene glycol; Alternatively, the polyol is mixed with water to form a solution, and the mass percentage of the polyol in the solution is 10 to 99%. Preferably, the mass percentage of the polyol in the solution is 50 to 80%.

6. The preparation method according to claim 5, characterized in that: In the polyol aqueous solution, the mass percentage of the composition according to claims 1 to 4 is 1 to 40%, preferably 2 to 10%.

7. Use of the composition according to any one of claims 1 to 4 in the preparation of a product for preventing or treating skin diseases caused by Malassezia, characterized in that: The skin diseases include tinea versicolor and Malassezia folliculitis.

8. The use according to claim 7, characterized in that The product is a medicine or a daily chemical product.

9. The use according to claim 8, characterized in that The medicine or daily chemical product is made of the composition and auxiliary materials allowed by the medicine or daily chemical product. In the medicine or daily chemical product, the mass percentage of the composition is 0.00001% to 99%.

10. The use according to claim 9, characterized in that The medicine or daily chemical product is an external-use product. The external-use product of the medicine is a lotion, ointment, emulsion or spray; the external-use product of the daily chemical product is a shampoo, conditioner, cream, hand soap, shower gel, essence or lotion, soap.

Images